Boy in science class

Science Class Starts Early If You Have An Autoimmune Disease Like Type 1 Diabetes (T1D)

Pere Sanatamaria

Navacims Are Breakthrough Science For Autoimmune Disease

Navacims

Navacims Are Nanoparticles Coated With Immune System Proteins To Fight Disease

Tailored Navacims

Navacims Can Be Tailored To Different Diseases Including T1D, Multiple Sclerosis & Arthritis

NavacimTD for T1D

NavacimTD In Development So That People With T1D Can Forget About Science And Just Be . . .

Freedom

Welcome

Parvus is a privately held biopharmaceutical company developing and commercializing a nanotechnology-based therapeutic platform for the treatment of autoimmunity.

We believe that our therapeutic candidates, Navacims, have the potential to radically improve the lives of patients with autoimmune disease. Navacims, are nanoparticles conjugated to immune system proteins that can be readily modified to target a range of autoimmune conditions like type I diabetes (T1D), multiple sclerosis and rheumatoid arthritis, amongst others. Our lead candidates reverse TID and Multiple Sclerosis in animals.

Management Team

  • President & CEO
    Phil Coggins joined Parvus on 25 May 2011, World MS Day, with more than 25 years in life science research and the biotech industry.
  • Chief Scientific Officer
    Pere Santamaria, an internationally recognized leader in diabetes research, is the scientific founder of Parvus.
  • VP Scientiifc Operations
    Jord Cowan joined Parvus in April 2012 from the company creation team at Innovate Calgary, where Parvus was launched.

Independent Directors

  • Jan LeCocq, Chair
    Jan is a managing partner of Collins Mabry & Co., former CEO at Gryphon Sciences and former CFO & Director at ICOS Corp.
  • Stephen Zaruby
    Steve is the former President of Zymogenetics, and before that a Vice President and Global Head at Bayer Healthcare.
  • Susan Clymer
    Susan is the founder of Nichi Bei Bio and co-founder of Sapient Health. She has deep experience in biotech BD and M&A.